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Background: Myocardial infarction (MI) is one of the main causes of
death in the world. Infarct size (IS) is associated with heart failure and mor-
tality following MI. Early reperfusion is currently the most effective treatment
to reduce IS resulting from MI. Although reperfusion reduces infarct size, it
can also lead to reperfusion injuries. Recently, it was shown that interleukin-
17A (IL-17A) is involved in the pathophysiology of reperfusion injuries.
However, the correlation between IS and the IL-17A level in humans is
unknown. Our aim was to evaluate whether the IL-17A serum level and the
IL-17A active fraction was correlated with IS in humans.
Methods: We selected 101 patients who presented with a ST-elevated
Myocardial Infarction (STEMI) and 10 healthy controls. For each patient
blood samples at admission (H0) and 4 hours after admission (H4) were col-
lected. IL-17A serum levels were assessed using ELISA and the active frac-
tion was assessed with a functional test. IS was determined by peak troponin
level and peak CK level for every patient and by cardiac magnetic resonance
imaging (CMR) for 20 patients.
Results: The IL-17A serum level was significantly increased in STEMI
patients compared to the healthy controls, showing a median value of 0.9 pg/mL
Interquartile Range IQR [0.0-3.2] at H0 and 1.0 pg/mL IQR [0.2-2.8] at H4
versus 0.2 pg/mL IQR [0.0-0.7] for healthy controls. The serum level of IL-17A
did not correlate with IS (r=–0.02475, p=0.80 at H0 and r=0.04425, p=0.66 at
H4 for peak troponin level; r=–0.03390, p=0.74 at H0 and r=0.02276, p=0.82 at
H4 for peak CK level and r=–0.2593, p=0.28 and r= –0.2884, p=0.23 for CMR).
As for the serum IL-17A level, no correlation was found between the active
fraction of IL-17A and IS.
Conclusion: Serum IL-17A level is significantly increased in patients at
the early phase of acute MI compared to healthy controls. However, the level
of IL-17A in the acute phase of MI does not correlate with IS.
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Metabolic syndrome is associated with a higher cardiac vulnerability to
ischemia-reperfusion (IR). Regular exercise is recognized to protect the heart.
This has been recently attributed to β3-adrenergic receptors (β3-AR) stimula-
tion and subsequent increase in endothelial nitric oxide synthase (eNOS) acti-
vation. However, the role of this pathway in exercise-induced cardioprotection
in animals with metabolic syndrome is unknown. We thus evaluated the role
of the β3-AR/eNOS pathway in exercise-induced cardioprotection in a mouse
model of metabolic syndrome. C57Bl6 mice were fed with high fat and
sucrose diet (HFS) for 12 weeks and some had treadmill-exercise with a
moderate intensity the last 4 weeks (HFS-Ex). First, HFS hearts were more
sensitive to IR, which was prevented by exercise. Even though exercise pro-
tects the HFS heart, this was not associated with increased activation state of
eNOS (level of eNOS-Pser1177 and the dimer/monomer ratio). Consequently,
no increase in NO metabolites storage was observed after exercise in HFS
hearts. This result may be explained by the loss of the β3-AR-eNOS pathway
in HFS hearts. Indeed, the use of BRL37344, an agonist of β3-AR, increased
eNOS-Pser1177 and protected the heart of Ctrl mice, whereas it had no effect
in HFS hearts. Finally, considering that exercise-induced cardioprotection is
also classically associated with increased antioxidant status, we next evaluated
ROS production during early reperfusion and the subsequent activation of the
apoptosis end-effector caspase 3. At early reperfusion we found that HFS
increased ROS and caspase 3 activation. This phenomenon was blunted in
HFS-Ex. Finally, a treatment with LPBNAH, a more amphiphilic nitrone
antioxidant derived from PBN normalized HFS heart vulnerability to IR. To
conclude these results showed that exercise-induced cardioprotection in HFS
hearts is independent of the classical β3-AR-eNOS pathway, but involved oxi-
dative stress during IR.
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Cardiovascular ischemic injuries are associated with vascular damage
induced by loss of endothelial junction integrity. Deciphering the mechanisms
involved in the regulation of vascular integrity is of major interest in order to
develop relevant therapeutic cardioprotective approaches to achieve tissue pro-
tection. Our team identified angiopoietin-like 4 (ANGPTL4) as a hypoxia-
induced target and a key regulator of vascular integrity by protecting inter-
endothelial cell junctions. However ANGPTL4 receptors and downstream
signaling pathways which mediate vasoprotective effect remain poorly inves-
tigated. Using both in vitro binding (Surface Plasmon Resonance, SPR) and
functional in vivo assays, we show that ANGPTL4 binds αvβ3 integrin and
that this interaction is necessary to mediate vasoprotective effects. In addition,
ANGPTL4 induces phosphorylation of Tyr773 of β3 integrin subunit and
reorganization of focal adhesions in endothelial cells. Mechanistically, binding
of ANGPTL4 to αvβ3 leads to Src recruitment and its sequestration away
from VEGFR2 combined to a diminished Src signaling downstream VEGFR2,
thereby inducing stabilization of both VEGFR2/VE-cadherin and VEGFR2/
αvβ3 complexes. Thus, ANGPTL4 strengthens maturation of adherens junc-
tions, characterized by a transition from a zipper to linear organization of VE-
cadherin organization.
Altogether, our results identify a novel mechanism by which ANGPTL4
counteracts hypoxia-driven vascular permeability through αvβ3 binding, modu-
lation of VEGFR2/Src kinase signaling and endothelial junction stabilization.
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Introduction: Obstructive sleep apnea (OSA) is a highly prevalent disease
characterized by repetitive upper airway collapse during sleep leading to
chronic intermittent hypoxia (IH). It has been shown in patients that OSA
contributes to myocardial infarct expansion. The lack of knowledge about the
mechanisms involved in OSA-associated cardiovascular complications had
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